{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T17:23:17Z","timestamp":1790875397431,"version":"4.1.0"},"reference-count":30,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100001849","name":"Defence Research and Development Organisation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001849","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Medical Journal Armed Forces India"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1016\/j.mjafi.2024.01.006","type":"journal-article","created":{"date-parts":[[2024,3,12]],"date-time":"2024-03-12T09:11:45Z","timestamp":1710234705000},"page":"429-437","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Heterogeneous ERBB gene pathways, their targeted treatment and possible molecular mechanisms of resistance in metastatic gallbladder cancer"],"prefix":"10.1016","volume":"81","author":[{"given":"Amol","family":"Patel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arti","family":"Sarin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-3735-1456","authenticated-orcid":false,"given":"Raghunath","family":"Marimuthu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charan Sai","family":"Madarapu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.G.","family":"Pandit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Divya","family":"Shelly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Sharanya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vidya","family":"Veldore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Suresh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.V.S.V.G.K.","family":"Tilak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.mjafi.2024.01.006_bib1","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1038\/ng.3375","article-title":"Genomic spectra of biliary tract cancer","volume":"47","author":"Nakamura","year":"2015","journal-title":"Nat Genet"},{"issue":"1","key":"10.1016\/j.mjafi.2024.01.006_bib2","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1007\/s10555-016-9645-x","article-title":"HER2\/HER3 pathway in biliary tract malignancies; systematic review and meta-analysis: a potential therapeutic target?","volume":"36","author":"Galdy","year":"2017","journal-title":"Cancer Metastasis Rev"},{"issue":"6","key":"10.1016\/j.mjafi.2024.01.006_bib3","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1177\/1756283X17698090","article-title":"The potential role of comprehensive genomic profiling to guide targeted therapy for patients with biliary cancer","volume":"10","author":"Lee","year":"2017","journal-title":"Therap Adv Gastroenterol"},{"issue":"8","key":"10.1016\/j.mjafi.2024.01.006_bib4","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1038\/ng.3030","article-title":"Whole-exome and targeted gene sequencing of gallbladder carcinoma identifies recurrent mutations in the ErbB pathway","volume":"46","author":"Li","year":"2014","journal-title":"Nat Genet"},{"key":"10.1016\/j.mjafi.2024.01.006_bib5","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1186\/s13045-015-0155-z","article-title":"HER2\/neu-directed therapy for biliary tract cancer","volume":"8","author":"Javle","year":"2015","journal-title":"J Hematol Oncol"},{"issue":"1","key":"10.1016\/j.mjafi.2024.01.006_bib6","article-title":"HER2 as a therapeutic target in gallbladder cancer\u2014aye or nay?","volume":"5","author":"Lam","year":"2016","journal-title":"Trans Cancer Res [Internet]"},{"issue":"2","key":"10.1016\/j.mjafi.2024.01.006_bib7","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1055\/s-0040-1721180","article-title":"Genomic landscape and targeted treatment of gallbladder cancer: results of a first ongoing prospective study","volume":"9","author":"Patel","year":"2020","journal-title":"South Asian J Cancer"},{"issue":"1","key":"10.1016\/j.mjafi.2024.01.006_bib8","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1615\/CritRevOncog.v17.i1.20","article-title":"Intrinsic and acquired resistance to HER2-targeted therapies in HER2 gene-amplified breast cancer: mechanisms and clinical implications","volume":"17","author":"Rexer","year":"2012","journal-title":"Crit Rev Oncog"},{"issue":"1","key":"10.1016\/j.mjafi.2024.01.006_bib9","doi-asserted-by":"crossref","first-page":"6667","DOI":"10.1038\/s41467-021-27093-y","article-title":"HER2 + breast cancers evade anti-HER2 therapy via a switch in driver pathway","volume":"12","author":"Smith","year":"2021","journal-title":"Nat Commun"},{"key":"10.1016\/j.mjafi.2024.01.006_bib10","article-title":"Drug-resistant HER2-positive breast cancer: molecular mechanisms and overcoming strategies","volume":"13","author":"Wu","year":"2022","journal-title":"Front Pharmacol"},{"issue":"12","key":"10.1016\/j.mjafi.2024.01.006_bib11","doi-asserted-by":"crossref","first-page":"e1303","DOI":"10.1634\/theoncologist.2018-0845","article-title":"Emergence of ERBB2 mutation as a biomarker and an actionable target in solid cancers","volume":"24","author":"Subramanian","year":"2019","journal-title":"Oncologist"},{"issue":"3_suppl l","key":"10.1016\/j.mjafi.2024.01.006_bib12","article-title":"Targeting HER2 (ERBB2) mutation-positive advanced biliary tract cancers with neratinib: results from the phase II SUMMIT \u2018basket\u2019 trial","volume":"39","author":"Harding","year":"2021","journal-title":"J Clin Orthod"},{"issue":"5","key":"10.1016\/j.mjafi.2024.01.006_bib13","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1016\/j.ccell.2018.09.010","article-title":"Actionable activating oncogenic ERBB2\/HER2 transmembrane and juxtamembrane domain mutations","volume":"34","author":"Pahuja","year":"2018","journal-title":"Cancer Cell"},{"issue":"7691","key":"10.1016\/j.mjafi.2024.01.006_bib14","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1038\/nature25475","article-title":"HER kinase inhibition in patients with HER2- and HER3-mutant cancers","volume":"554","author":"Hyman","year":"2018","journal-title":"Nature"},{"issue":"9","key":"10.1016\/j.mjafi.2024.01.006_bib15","doi-asserted-by":"crossref","first-page":"761","DOI":"10.4251\/wjgo.v11.i9.761","article-title":"Gallbladder cancer harboring ERBB2 mutation on the primary and metastatic site: a case report","volume":"11","author":"Inagaki","year":"2019","journal-title":"World J Gastrointest Oncol"},{"issue":"12","key":"10.1016\/j.mjafi.2024.01.006_bib16","doi-asserted-by":"crossref","first-page":"2845","DOI":"10.1002\/ijc.26292","article-title":"Clinicopathologic factors associated with HER2-positive gastric cancer and its impact on survival outcomes--a systematic review","volume":"130","author":"Chua","year":"2012","journal-title":"Int J Cancer"},{"issue":"3","key":"10.1016\/j.mjafi.2024.01.006_bib17","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1634\/theoncologist.2011-0311","article-title":"Targeted therapy in the management of advanced gastric cancer: are we making progress in the era of personalized medicine?","volume":"17","author":"Wong","year":"2012","journal-title":"Oncol"},{"issue":"3","key":"10.1016\/j.mjafi.2024.01.006_bib18","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2016-013053","article-title":"Efficacy and safety of lapatinib and trastuzumab for HER2-positive breast cancer: a systematic review and meta-analysis of randomised controlled trials","volume":"7","author":"Xu","year":"2017","journal-title":"BMJ Open"},{"issue":"6","key":"10.1016\/j.mjafi.2024.01.006_bib19","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1016\/S1470-2045(16)00150-9","article-title":"Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12\/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial","volume":"17","author":"Sartore-Bianchi","year":"2016","journal-title":"Lancet Oncol"},{"issue":"6","key":"10.1016\/j.mjafi.2024.01.006_bib20","doi-asserted-by":"crossref","first-page":"2768","DOI":"10.1177\/0300060519847796","article-title":"Dual-targeting strategy using trastuzumab and lapatinib in a patient with HER2 gene amplification in recurrent metachronous metastatic gallbladder carcinoma","volume":"47","author":"Ye","year":"2019","journal-title":"J Int Med Res"},{"issue":"1","key":"10.1016\/j.mjafi.2024.01.006_bib21","doi-asserted-by":"crossref","first-page":"75","DOI":"10.4103\/0377-4929.94862","article-title":"Role of C-erbB2 expression in gallbladder cancer","volume":"55","author":"Kumari","year":"2012","journal-title":"Indian J Pathol Microbiol"},{"issue":"1","key":"10.1016\/j.mjafi.2024.01.006_bib22","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa2203690","article-title":"Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer","volume":"387","author":"Modi","year":"2022","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.mjafi.2024.01.006_bib23","article-title":"Supplement: abstracts from the fifteenth rambam Research day, december 20, 2018","volume":"10","year":"2019","journal-title":"Rambam Maimonides Med J"},{"key":"10.1016\/j.mjafi.2024.01.006_bib24","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1007\/978-1-62703-727-3_24","article-title":"ERBB4 mutation analysis: emerging molecular target for melanoma treatment","volume":"1102","author":"Lau","year":"2014","journal-title":"Methods Mol Biol"},{"issue":"8","key":"10.1016\/j.mjafi.2024.01.006_bib25","article-title":"Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer","volume":"1","author":"Do-Youn","year":"2022","journal-title":"NEJM Evidence"},{"issue":"315","key":"10.1016\/j.mjafi.2024.01.006_bib26","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aac4925","article-title":"Trastuzumab emtansine (T-DM1) renders HER2+ breast cancer highly susceptible to CTLA-4\/PD-1 blockade","volume":"7","author":"M\u00fcller","year":"2015","journal-title":"Sci Transl Med"},{"issue":"3","key":"10.1016\/j.mjafi.2024.01.006_bib27","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/S1470-2045(18)30812-X","article-title":"Pembrolizumab plus trastuzumab in trastuzumab-resistant, advanced, HER2-positive breast cancer (PANACEA): a single-arm, multicentre, phase 1b-2 trial","volume":"20","author":"Loi","year":"2019","journal-title":"Lancet Oncol"},{"issue":"6","key":"10.1016\/j.mjafi.2024.01.006_bib28","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1016\/S1470-2045(20)30169-8","article-title":"First-line pembrolizumab and trastuzumab in HER2-positive oesophageal, gastric, or gastro-oesophageal junction cancer: an open-label, single-arm, phase 2 trial","volume":"21","author":"Janjigian","year":"2020","journal-title":"Lancet Oncol"},{"issue":"10","key":"10.1016\/j.mjafi.2024.01.006_bib29","doi-asserted-by":"crossref","DOI":"10.15252\/embr.201948058","article-title":"CDK12 drives breast tumor initiation and trastuzumab resistance via WNT and IRS1-ErbB-PI3K signaling","volume":"20","author":"Choi","year":"2019","journal-title":"EMBO Rep"},{"key":"10.1016\/j.mjafi.2024.01.006_bib30","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/s13008-017-0033-x","article-title":"The emerging roles of CDK12 in tumorigenesis","volume":"12","author":"Paculov\u00e1","year":"2017","journal-title":"Cell Div"}],"container-title":["Medical Journal Armed Forces India"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S037712372400008X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S037712372400008X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T00:47:48Z","timestamp":1762303668000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S037712372400008X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":30,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["S037712372400008X"],"URL":"https:\/\/doi.org\/10.1016\/j.mjafi.2024.01.006","relation":{},"ISSN":["0377-1237"],"issn-type":[{"value":"0377-1237","type":"print"}],"subject":[],"published":{"date-parts":[[2025,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Heterogeneous ERBB gene pathways, their targeted treatment and possible molecular mechanisms of resistance in metastatic gallbladder cancer","name":"articletitle","label":"Article Title"},{"value":"Medical Journal Armed Forces India","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.mjafi.2024.01.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Director General, Armed Forces Medical Services. Published by Elsevier, a division of RELX India Pvt. Ltd.","name":"copyright","label":"Copyright"}]}}